Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Research analysts at Oppenheimer Holdings boosted their FY2017 earnings estimates for Syros Pharmaceuticals in a research report issued to clients and investors on Wednesday. Oppenheimer Holdings analyst L. Cann now anticipates that the company will post earnings per share of ($2.10) for the year, up from their prior forecast of ($2.13). Oppenheimer Holdings also issued estimates for Syros Pharmaceuticals’ Q4 2017 earnings at ($0.56) EPS, Q1 2018 earnings at ($0.88) EPS, Q2 2018 earnings at ($0.91) EPS, Q3 2018 earnings at ($0.94) EPS, Q4 2018 earnings at ($0.97) EPS, FY2018 earnings at ($3.69) EPS, FY2019 earnings at ($2.87) EPS and FY2020 earnings at ($0.88) EPS.
Several other brokerages have also recently weighed in on SYRS. JMP Securities cut shares of Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 10th. Wedbush restated an “outperform” rating and issued a $22.84 price target (down previously from $25.00) on shares of Syros Pharmaceuticals in a research report on Thursday, August 10th. Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, August 9th. Cann restated a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. Finally, Zacks Investment Research cut shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $26.14.
Shares of Syros Pharmaceuticals (SYRS) opened at $11.57 on Monday. Syros Pharmaceuticals has a 1 year low of $10.22 and a 1 year high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.53).
Institutional investors and hedge funds have recently made changes to their positions in the stock. Nationwide Fund Advisors increased its position in Syros Pharmaceuticals by 249.8% in the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after purchasing an additional 5,016 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Syros Pharmaceuticals during the third quarter valued at $133,000. Cubist Systematic Strategies LLC bought a new position in Syros Pharmaceuticals during the third quarter valued at $149,000. The Manufacturers Life Insurance Company increased its position in Syros Pharmaceuticals by 11,253.8% during the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock valued at $170,000 after acquiring an additional 10,466 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Syros Pharmaceuticals during the first quarter valued at $185,000. Institutional investors own 54.15% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.